IL228203A - Antibodies against 4-ctla - Google Patents
Antibodies against 4-ctlaInfo
- Publication number
- IL228203A IL228203A IL228203A IL22820313A IL228203A IL 228203 A IL228203 A IL 228203A IL 228203 A IL228203 A IL 228203A IL 22820313 A IL22820313 A IL 22820313A IL 228203 A IL228203 A IL 228203A
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- humanised anti
- anti ctla
- ctla
- humanised
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161450896P | 2011-03-09 | 2011-03-09 | |
| GBGB1103955.9A GB201103955D0 (en) | 2011-03-09 | 2011-03-09 | Antibodies |
| PCT/EP2012/054144 WO2012120125A1 (en) | 2011-03-09 | 2012-03-09 | Humanised anti ctla-4 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL228203A true IL228203A (en) | 2017-12-31 |
Family
ID=43923406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL228203A IL228203A (en) | 2011-03-09 | 2013-08-29 | Antibodies against 4-ctla |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9714290B2 (https=) |
| EP (1) | EP2683739B1 (https=) |
| JP (1) | JP6211930B2 (https=) |
| KR (1) | KR20140033013A (https=) |
| CN (1) | CN103547595B (https=) |
| AU (1) | AU2012224511B2 (https=) |
| BR (1) | BR112013022797A2 (https=) |
| CA (1) | CA2828528C (https=) |
| DK (1) | DK2683739T3 (https=) |
| ES (1) | ES2571129T3 (https=) |
| GB (1) | GB201103955D0 (https=) |
| IL (1) | IL228203A (https=) |
| MX (1) | MX344971B (https=) |
| MY (1) | MY166776A (https=) |
| RU (1) | RU2629768C2 (https=) |
| SG (1) | SG192969A1 (https=) |
| WO (1) | WO2012120125A1 (https=) |
| ZA (1) | ZA201306589B (https=) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| TWI687439B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| EP2877589B1 (en) | 2012-07-26 | 2024-03-06 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
| WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| RS59756B1 (sr) | 2013-08-08 | 2020-02-28 | Cytune Pharma | Kombinovana farmaceutska kompozicija |
| PT3444271T (pt) | 2013-08-08 | 2022-01-05 | Inst Nat Sante Rech Med | Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| EP3090066A4 (en) * | 2014-01-02 | 2017-08-30 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| CA2957717C (en) | 2014-08-12 | 2021-10-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein |
| JP6991857B2 (ja) | 2014-10-10 | 2022-01-13 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療 |
| US10983128B2 (en) | 2015-02-05 | 2021-04-20 | Bristol-Myers Squibb Company | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy |
| EP3256165B1 (en) * | 2015-02-13 | 2021-07-14 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
| JP6649941B2 (ja) * | 2015-02-16 | 2020-02-19 | 株式会社ファーマフーズ | Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤 |
| MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| CA2991628C (en) | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| CN107406504B (zh) * | 2015-11-19 | 2021-04-30 | 蔡则玲 | Ctla-4抗体及其用途 |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| ES2979210T3 (es) * | 2015-12-15 | 2024-09-24 | Oncoc4 Inc | Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos |
| MA43587A (fr) | 2016-01-10 | 2018-11-14 | Modernatx Inc | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 |
| JP7137474B2 (ja) | 2016-03-15 | 2022-09-14 | メルサナ セラピューティクス，インコーポレイティド | ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法 |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| EA039322B1 (ru) * | 2016-04-15 | 2022-01-13 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
| JP2019519516A (ja) | 2016-05-18 | 2019-07-11 | モデルナティーエックス， インコーポレイテッド | がんの治療のためのｍＲＮＡ併用療法 |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| AU2017290828A1 (en) | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| US20190365657A1 (en) * | 2016-08-17 | 2019-12-05 | Orbis Health Solutions, Llc | Tumor-targeting bead vectors and methods of using the same |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2018035710A1 (en) * | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN107815467B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018041121A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ctla-4 |
| CN107815468B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| JP7066696B2 (ja) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| DK3551660T5 (da) * | 2016-12-07 | 2024-09-02 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| US20200095301A1 (en) | 2016-12-14 | 2020-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
| AU2018207303A1 (en) | 2017-01-10 | 2019-07-25 | xCella Biosciences, Inc. | Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator |
| JP7165995B2 (ja) * | 2017-02-21 | 2022-11-07 | アールイーエムディー バイオセラピューティクス，インコーポレイテッド | 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療 |
| AU2018227428A1 (en) * | 2017-02-28 | 2019-10-17 | Bristol-Myers Squibb Company | Use of anti-CTLA-4 antibodies with enhanced ADCC to enhance immune response to a vaccine |
| US20180271996A1 (en) | 2017-02-28 | 2018-09-27 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| EP3597735A4 (en) * | 2017-03-15 | 2020-11-25 | Suzhou Galaxy Biopharma, Co., Ltd. | CTLA4 ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USES THEREOF |
| CN116478289A (zh) * | 2017-05-19 | 2023-07-25 | 上海药明生物技术有限公司 | 一种新的ctla-4单克隆抗体 |
| JP7173993B2 (ja) | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| WO2019020807A1 (en) * | 2017-07-28 | 2019-01-31 | Gene Signal International Sa | CD9P-1 TARGETING ANTIBODIES AND USES THEREOF |
| JP2020528932A (ja) * | 2017-07-28 | 2020-10-01 | ジーン シグナル インターナショナル ソシエテ アノニム | Ｃｄ９ｐ−１標的化抗体およびその使用 |
| CA3073984A1 (en) * | 2017-09-21 | 2019-03-28 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ctla4 antibodies and uses thereof |
| WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| SG11202005692WA (en) * | 2017-12-20 | 2020-07-29 | Harbour Biomed Shanghai Co Ltd | Antibodies binding ctla-4 and uses thereof |
| CN111757757A (zh) | 2017-12-21 | 2020-10-09 | 梅尔莎纳医疗公司 | 吡咯并苯并二氮呯抗体共轭物 |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| US12590133B2 (en) | 2018-06-01 | 2026-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CN110760002A (zh) | 2018-07-25 | 2020-02-07 | 南京金斯瑞生物科技有限公司 | 人源化抗人ctla4单克隆抗体及其制备方法和用途 |
| CN120365435A (zh) | 2018-08-30 | 2025-07-25 | 免疫生物公司 | 单链嵌合多肽和多链嵌合多肽以及其用途 |
| CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
| EP3843788A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| AU2019346335B2 (en) | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| CN113365664A (zh) | 2018-10-29 | 2021-09-07 | 梅尔莎纳医疗公司 | 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物 |
| BR112021008060A2 (pt) * | 2018-10-31 | 2021-11-23 | Bioatla Inc | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento |
| KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| CA3122773A1 (en) | 2018-12-26 | 2020-07-02 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
| SG11202106764YA (en) * | 2018-12-27 | 2021-07-29 | Gigagen Inc | Anti-ctla-4 binding proteins and methods of use thereof |
| EP3914289A1 (en) | 2019-01-23 | 2021-12-01 | Massachusetts Institute of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| TWI869398B (zh) * | 2019-05-10 | 2025-01-11 | 英商拜西克爾德有限公司 | 治療癌症之方法 |
| CA3141626A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| JP7713393B2 (ja) | 2019-06-21 | 2025-07-25 | イミュニティーバイオ インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| WO2020263399A1 (en) | 2019-06-26 | 2020-12-30 | Massachusetts Institute Of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| WO2021009188A1 (en) | 2019-07-15 | 2021-01-21 | Intervet International B.V. | Caninized antibodies to human and canine ctla-4 |
| CA3145345A1 (en) | 2019-07-15 | 2021-01-21 | Intervet International B.V. | Caninized antibodies against canine ctla-4 |
| CN110467675B (zh) * | 2019-09-19 | 2020-08-14 | 合源生物科技(天津)有限公司 | 一种ctla-4单克隆抗体6f1及其用于抗肿瘤的用途 |
| US11459389B2 (en) | 2019-10-24 | 2022-10-04 | Massachusetts Institute Of Technology | Monoclonal antibodies that bind human CD161 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| UA128549C2 (uk) | 2019-12-27 | 2024-08-07 | Чугаі Сейяку Кабусікі Кайся | Антитіло до ctla-4 та його застосування |
| CA3165927A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| US12115191B2 (en) | 2020-02-11 | 2024-10-15 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| US20230149560A1 (en) | 2020-04-20 | 2023-05-18 | Massachusetts Institute Of Technology | Lipid compositions for delivery of sting agonist compounds and uses thereof |
| CN115997008A (zh) | 2020-04-22 | 2023-04-21 | 艾欧凡斯生物治疗公司 | 协调用于患者特异性免疫疗法的细胞的制造的系统和方法 |
| EP4143231A1 (en) | 2020-04-29 | 2023-03-08 | HCW Biologics, Inc. | Anti-cd26 proteins and uses thereof |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4157460A1 (en) | 2020-06-01 | 2023-04-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021250594A1 (en) * | 2020-06-11 | 2021-12-16 | Nantbio, Inc. | Anti-ctla4 monoclonal antibodies and chimeric antigen receptors |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| KR20230033719A (ko) * | 2020-07-02 | 2023-03-08 | 기가젠, 인코포레이티드 | 항-ctla-4 결합 단백질 및 이의 사용 방법 |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022169269A1 (ko) * | 2021-02-03 | 2022-08-11 | 주식회사 유틸렉스 | 항 ctla-4 항체 및 이의 용도 |
| JP2024512029A (ja) | 2021-03-25 | 2024-03-18 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用 |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| US12448451B2 (en) | 2021-06-25 | 2025-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
| AR126220A1 (es) | 2021-06-25 | 2023-09-27 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-ctla-4 |
| TWI879694B (zh) | 2021-06-25 | 2025-04-01 | 日商中外製藥股份有限公司 | 抗ctla-4抗體的用途 |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
| EP4507711A1 (en) | 2022-04-13 | 2025-02-19 | ImmunityBio, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
| JP2025512401A (ja) | 2022-04-15 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| JP2025539816A (ja) | 2022-11-21 | 2025-12-09 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026043906A1 (en) | 2024-08-19 | 2026-02-26 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| US20260049118A1 (en) | 2024-08-19 | 2026-02-19 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB9712892D0 (en) | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| CZ302706B6 (cs) * | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| AU7337400A (en) | 1999-09-03 | 2001-04-10 | Human Genome Sciences, Inc. | B7-like polynucleotides, polypeptides, and antibodies |
| JP2003520828A (ja) * | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| WO2001054731A2 (en) | 2000-01-28 | 2001-08-02 | National University Of Singapore | Ligand conjugates and methods for preparing same |
| NZ536420A (en) * | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| SG144925A1 (en) * | 2003-08-04 | 2008-08-28 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| US7264806B2 (en) * | 2003-11-01 | 2007-09-04 | Biovation Ltd. | Modified anti-CD52 antibody |
| AU2006210724A1 (en) | 2005-02-03 | 2006-08-10 | Antitope Limited | Human antibodies and proteins |
| JP2006265244A (ja) * | 2005-03-23 | 2006-10-05 | Pfizer Prod Inc | Ｃｔｌａ４抗体とホルモン治療を用いた前立腺癌の治療 |
| KR101485202B1 (ko) * | 2006-10-11 | 2015-01-22 | 안티토페 리미티드 | Ｔ 세포 에피토프 데이터베이스들 |
| NZ713461A (en) * | 2011-04-15 | 2017-02-24 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| ES2989943T3 (es) * | 2011-05-13 | 2024-11-28 | Astellas Pharma Inc | Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6 |
-
2011
- 2011-03-09 GB GBGB1103955.9A patent/GB201103955D0/en not_active Ceased
-
2012
- 2012-03-09 RU RU2013145243A patent/RU2629768C2/ru active
- 2012-03-09 MX MX2013010268A patent/MX344971B/es active IP Right Grant
- 2012-03-09 EP EP12708319.4A patent/EP2683739B1/en active Active
- 2012-03-09 ES ES12708319T patent/ES2571129T3/es active Active
- 2012-03-09 JP JP2013557119A patent/JP6211930B2/ja active Active
- 2012-03-09 BR BR112013022797A patent/BR112013022797A2/pt not_active IP Right Cessation
- 2012-03-09 CN CN201280022428.5A patent/CN103547595B/zh active Active
- 2012-03-09 MY MYPI2013003297A patent/MY166776A/en unknown
- 2012-03-09 AU AU2012224511A patent/AU2012224511B2/en not_active Ceased
- 2012-03-09 CA CA2828528A patent/CA2828528C/en active Active
- 2012-03-09 WO PCT/EP2012/054144 patent/WO2012120125A1/en not_active Ceased
- 2012-03-09 DK DK12708319.4T patent/DK2683739T3/en active
- 2012-03-09 SG SG2013064845A patent/SG192969A1/en unknown
- 2012-03-09 KR KR1020137026648A patent/KR20140033013A/ko not_active Ceased
- 2012-03-09 US US14/003,900 patent/US9714290B2/en active Active
-
2013
- 2013-08-29 IL IL228203A patent/IL228203A/en not_active IP Right Cessation
- 2013-09-02 ZA ZA2013/06589A patent/ZA201306589B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9714290B2 (en) | 2017-07-25 |
| MX344971B (es) | 2017-01-12 |
| MX2013010268A (es) | 2014-03-27 |
| JP6211930B2 (ja) | 2017-10-11 |
| SG192969A1 (en) | 2013-09-30 |
| DK2683739T3 (en) | 2016-05-23 |
| ZA201306589B (en) | 2014-05-28 |
| AU2012224511A1 (en) | 2013-09-19 |
| RU2629768C2 (ru) | 2017-09-06 |
| GB201103955D0 (en) | 2011-04-20 |
| CN103547595A (zh) | 2014-01-29 |
| EP2683739A1 (en) | 2014-01-15 |
| AU2012224511B2 (en) | 2016-09-29 |
| EP2683739B1 (en) | 2016-03-09 |
| CN103547595B (zh) | 2017-05-31 |
| ES2571129T3 (es) | 2016-05-24 |
| MY166776A (en) | 2018-07-23 |
| JP2014512809A (ja) | 2014-05-29 |
| RU2013145243A (ru) | 2015-04-20 |
| US20140105914A1 (en) | 2014-04-17 |
| BR112013022797A2 (pt) | 2016-12-06 |
| CA2828528C (en) | 2020-04-21 |
| KR20140033013A (ko) | 2014-03-17 |
| WO2012120125A1 (en) | 2012-09-13 |
| CA2828528A1 (en) | 2012-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201306589B (en) | Humanised anti ctla-4 antibodies | |
| IL272035A (en) | Anti IL–36R antibodies | |
| TWI561531B (en) | Anti b7-h3 antibody | |
| ZA201400768B (en) | Interleukin-31 monoclonal antibody | |
| ZA201403864B (en) | Humanized antibodies that recognize alpha-synuclein | |
| IL220404A (en) | Antiseptic antibodies | |
| IL229713A0 (en) | Humanized antibodies against cd52 | |
| PH12012501884A1 (en) | Humanized il-25 antibodies | |
| IL231075A (en) | Antibodies against human xcr1 | |
| EP2707392A4 (en) | MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| MM9K | Patent not in force due to non-payment of renewal fees |